Abstract

BASIC RESEARCH GROUP CORE 004 ? BIOANALYTICS AND PROTEOMICS SHARED RESOURCE PROJECT SUMMARY/ABSTRACT The mission of the Bioanalytics & Proteomics Shared Resource (BPSR) is to provide cost-effective, state-of- the-art instrumentation and analytical expertise in mass spectrometry to investigators in the Vanderbilt-Ingram Cancer Center (VICC). The BPSR is centrally located on the Vanderbilt campus and is composed of three components that provide the following analytical services: 1) bioanalytical and drug metabolite, 2) analytical proteomics, and 3) molecular profiling and tissue imaging. The BPSR staff provides consultation on experimental design and sample preparation, as well as performs all aspects of mass spectrometry analyses and data analysis. LC-MS/MS, GC-MS and MALDI-TOF instruments are available for small molecule drug and metabolite analysis. LC-MS/MS and MALDI-TOF/TOF instrumentation are available for proteomics analysis, including MUDPIT, SILAC and iTRAQ. A variety of MALDI-based instruments are provided for molecular profiling and tissue imaging experiments. In addition, ICP-MS capabilities are offered for elemental analysis and tissue imaging. Specific services include identification and quantification of small molecules in biofluids and tissues, identification and quantification of proteins and their modifications, and imaging of small molecules and protein in tissues using imaging mass spectrometry. The BPSR staff provides education and training in sample preparation, instrumental analysis and data analysis to VICC investigators and their laboratory personnel. Lastly, the BPSR collaborates with VICC proteomics experts to continue to offer the latest cutting- edge technology and methods in bimolecular mass spectrometry analysis for high-impact cancer discovery.

Public Health Relevance

BASIC RESEARCH GROUP CORE 004 ? BIOANALYTICAL AND PROTEOMICS SHARED RESOURCE PROJECT NARRATIVE Per the PAR-13-386 FOA, the project narrative is not applicable for the Bioanalytical and Proteomics Shared Resource.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-21
Application #
9152299
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Marino, Michael A
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
21
Fiscal Year
2016
Total Cost
$348,178
Indirect Cost
$126,409

  Institution

Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232

  Publications

Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications